Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UGN-101 Retreatment in Recurrent LG UTUC
NCT04006691Phase 3Withdrawn
- Sponsor
- UroGen Pharma
- Start
- Oct 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of UGN-103 in upper tract urothelial carcinoma (UTUC), sponsored by UroGen Pharma. Planned start Oct 2019; status: withdrawn.
02
Drugs
UGN-103
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT04006691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04006691.